Septerna (SEPN) presented an update on its expanding drug-development pipeline and financial position at the 12th Annual Cantor Fitzgerald Global Healthcare Conference on September 10, 2026, as investors tracked the company’s progression across multiple therapeutic areas.
Shares traded around $37.98 to $38.09, reflecting modest gains during the session, and the company holds a market capitalization of $1.77 billion. Analysts’ price targets for the stock range from $48 to $62. Over the past year, Septerna’s shares have returned 158%, with a 36% gain year to date.
The company entered the second quarter with $516 million in cash and cash equivalents, management said, projecting a funded runway into at least 2029. Septerna reported a debt-to-equity ratio of 0.06 and a current ratio of 4.99. Revenue growth came in above 13,000% over the trailing twelve months, a figure that Co-founder and CEO Jeff Finer noted stems from a small base tied to the company’s collaboration with Novo Nordisk.
Under the partnership with Novo Nordisk, Septerna is active across five metabolic targets, three of which have been disclosed. The collaboration contributes to revenue despite the company remaining pre-commercial for its own approved product pipeline.
SEP-479, Septerna’s lead small-molecule agonist targeting the parathyroid hormone receptor for hypoparathyroidism, is advancing in Phase I single-ascending-dose and multiple-ascending-dose studies in Australia. The compound has a half-life of approximately three to four days, Finer described as an “absolute sweet spot.” Phase II trials are planned to enroll dozens of patients over roughly a 12-week dosing period, with Phase III pivotal studies expected to enroll about 100 patients each. Yorvipath, an injectable PTH therapy that won approval in roughly 35 countries, was cited as the benchmark against which SEP-479’s design was evaluated.
For SEP-631, a MRGPRX2 inhibitor aimed at mast cell-driven diseases, Septerna completed a Phase I study reporting a clean safety profile. The program shifted away from a large Phase II trial in chronic spontaneous urticaria after two prior CSU trials failed in that indication. Management instead is moving toward smaller signal-finding, biomarker-led studies evaluating conditions including interstitial cystitis, asthma, and migraine. Finer noted that achieving 99.9% receptor occupancy — up from the 95% level observed in early studies — will be needed for a full therapeutic effect.
Septerna also provided updates on its TSH receptor program targeting Graves’ disease and thyroid eye disease, which targets the transmembrane domain of the receptor, distinct from where autoantibodies bind the extracellular domain. The compound reversed elevated thyroid hormone levels, enlarged thyroid size, and proptosis in an in-house-developed Graves’ mouse model. Finer said the program had required extended optimization to balance potency and pharmaceutical properties across multiple compound series, adding, “we now think we’ve cracked it.” The TSH receptor program was expected to become an important part of the portfolio in 2025.
An early discovery-stage osteoporosis program uses a short-acting PTH agonist and leverages a recent FDA regulatory change allowing bone mineral density to serve as a surrogate endpoint for studies lasting roughly 12 months.
